| Theme | Update of PET Diagnosis for Cancer of Digestive Organs | |
|---|---|---|
| Title | Clinical Usefulness of FDG-PET in Management of Malignant Hepato-Biliary-Pancreatic Diseases | |
| Publish Date | 2009/03 | |
| Author | Ryuichiro Doi | Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kyoto University |
| Author | Satoru Seo | Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kyoto University |
| Author | Kazuhiro Kami | Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kyoto University |
| Author | Shinji Uemoto | Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kyoto University |
| [ Summary ] | Currently, in Japan, the cost of FDG-PET imaging is covered by public health insurance only for the clinical treatment of pancreatic cancer and metastatic liver tumors in the field of hepato-biliary pancreatic diseases. However, its utility for other diseases such as hepatocellular carcinoma and cholangiocarcinoma, has been tested in clinical trials. FDG-PET imaging is useful for the identification of malignant tumors, distant metastases, and recurrent tumors in post-treatment settings. In addition, FDG-PET imaging is useful for evaluation of the effects of chemotherapy and radiation therapy. The limitations of PET include false positive readings due to diabetes mellitus or inflammation. The clinical significance of FDG-PET imaging is limited, therefore it is most useful for hepato-biliary pancreatic diseases with the concomitant use of CTS or MRIS. | |